Servier agreed to acquire Edgewise Therapeutics’ muscular dystrophy assets in a transaction worth up to $2.65 billion, centered on sevasemten. The deal includes a $1.55 billion upfront payment plus potential milestones of up to $1.1 billion, with Servier expecting pivotal trial data to arrive this year. Sevasemten is being studied in a pivotal trial for Becker muscular dystrophy and a Phase 2 program in Duchenne muscular dystrophy. The oral drug is intended to protect muscles from ongoing damage in both rare neuromuscular conditions. The acquisition meaningfully consolidates risk and timelines for a late-stage neurology asset, offering Servier a path to move from development into potential regulatory review schedules dependent on trial readouts.